Prodotti competitors / Area HIV 13 marzo 2024 ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
Prodotti competitors / Area HIV 6 marzo 2024 ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
Prodotti competitors / Area HIV 1 marzo 2024 CROI 2024: ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Autorità nazionali 13 febbraio 2024 GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Prodotti competitors 19 gennaio 2024 HIV competitive landscape: Viiv Phase 2a Trial with VH184 in TN PLWH Initiated
Prodotti competitors / Area Onco-Ema 27 novembre 2023 Blenrep (belantamab mafodotin) plus bortezomib plus dexamethasone (BorDex) showed statistically significant progression-free survival (PFS) benefit in relapsed/refractory multiple myeloma patients
Prodotti competitors / Area Liver 3 novembre 2023 Viral Hepatitis HBV/HBV Cure: GSK prominently featured bepirovirsen development and J&J siRNA licensing deal
Prodotti competitors 19 ottobre 2023 ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
Prodotti competitors / Area Liver 12 ottobre 2023 GSK reveals positive but lackluster data from the Ph2b B-Together study (bepirovirsen + pegIFN) in AASLD 2023 abstract
Prodotti competitors / Area Liver 29 settembre 2023 Viral Hepatitis HBV/HBV Cure: GSK and VIR continue to invest in HBV Cure with expanded clinical development programs
